Medical product for calf diarrhea treatment
FIELD: medicine; veterinary medicine.
SUBSTANCE: medical product contains polyvinylpyrolidone, Furacilinum, glucose, Acidum ascorbinicum and sodium hypochlorite at the certain component proportion.
EFFECT: reduction of diarrhea duration on 36% (to 2.8 days); calf safety at level of 95% and additional weight increase on 15-44% after treatment, reduction of medical products consumption.
2 tbl, 2 ex
The invention relates to veterinary medicine, in particular drugs for the treatment of diarrhea in animals.
Known drug - solution of gentamicin (1 ml of solution contains 40 mg of gentamicin in the form of sulfate, which has a wide spectrum of action), used to treat and prevent infections of the gastrointestinal tract, respiratory and urinary tract in a dose of 3 mg/kg of body weight of the calf 2 times a day for 3-5 days. (See Guidance on the application of a solution of gentamicin in veterinary medicine. Approved by the Deputy head of the veterinary Department).
However, the use of antibiotics in mass diseases are often carried out without taking into account the laboratory diagnosis of drug sensitivity to pathogenic microflora, requiring additional time to research and, as a consequence, accompanied by the disruption of the microbial balance in the digestive tract secondary dysbacteriosis. In addition, the conditions for the development of more selective pathogens and drug-resistant strains of microorganisms in the background accompanied by a reduction in resistance of the organism.
Known drug for the treatment of diarrhoea in calves is a solution of sodium hypochlorite at a concentration of 300-500 mg/l in a volume of 500 ml, which vapiwala for 30 minutes before feeding 2 times a day until recovery within 35 days. Active sodium hypochlorite solution produced by electrolysis of sodium chloride solution on the apparatus EDO-4. (See "The effectiveness of dosage forms of sodium hypochlorite", Journal of veterinary medicine", No. 4, 1992, p.14).
However, active sodium hypochlorite solution set in large doses (500 ml), does not provide a high therapeutic efficacy in an associative basis, and, being a powerful oxidant in large doses, reduces the effect of symptomatic means. In addition, as shown, the feeding of high doses (500 ml) of sodium hypochlorite is difficult because of its strong odor, at a concentration of 500 mg/l calves refuse to drink the solution even in a mixture with milk.
Known drug lers for the treatment of diarrhoea of calves. Lars helps to remove toxins from the gastrointestinal tract and prevents the rennet casein of does, normalizes water-salt balance, has a bacteriostatic effect. The drug is a set - packing powdery substances, put up in three packages. Package # 1 - polyvinylpyrrolidone (PVP) - 200 g package # 2 - glucose 200 g package # 3: potassium chloride 2 g, sodium chloride 50 g aminouksusnoy acid (glycocol) 30 g calcium lactate 10 g ascorbic acid 5 g, ethacridine lactate 2 g furatsilin 1, the Drug is prepared in the form of a solution from the contents of the three packages in 10 l of water (70-80° C). With the preventive purpose of the calves during the first 6 vipac after birth, feeding 250 ml each portion of colostrum, for therapeutic purposes calves the next 2 feeding milk substitute solution Larsa in volume of one liter at a time, in the subsequent portion of milk add 250 ml of Larsa to recovery. (See Instructions for manufacturing and production control drug lers. Approved by the Ministry of Agriculture of the USSR. The main veterinary Department November, 1985 Interim guidance on the use of the drug Lars - prototype).
However, this drug is cumbersome due to the necessity of preparation of a solution directly into the economy, where conditions generally do not meet the requirements of the veterinary-sanitary standards required for the preparation of medicinal products (microbial contamination during preparation and periodic mixing during the day). In addition hindered the application instructions specified drugs in large volumes with poor performance, high flow components.
It is necessary to develop a comprehensive drug for the treatment of diarrhoea of calves, efficiency-enhancing treatment that promotes safety calves, reducing treatment time with minimal doses of drugs is a, loss reduction in average daily gain, to the exclusion of incidental and negative effects when using the drug.
This technical result is achieved by the fact that the medicinal product, including polyvinylpyrrolidone, furatsilin, glucose, ascorbic acid additionally contains sodium hypochlorite with a concentration of 300-350 mg/l, with the following ratio of components, g/l: polyvinylpyrrolidone 9-10, furatsilin 5-6, glucose 18-20, ascorbic acid 4 sodium hypochlorite to liters, while the daily dose of the drug, administered for 2-3 times with colostrum or milk is not more than 150 ml
The essence of the claimed medicinal product is that studies the applicant identified the optimal combination of drugs (part of the comprehensive drug lers and sodium hypochlorite), which significantly reduced the daily dose of the drug, administered to the newborn calves (6-8 times), reduced consumption, polyvinylpyrrolidone and glucose. So with one liter of Larsa consumed 20 g of polyvinylpyrrolidone and 20 g of glucose, while 150 ml (daily dose) declared funds 1.5 g of polyvinylpyrrolidone and 3.0 g of glucose (average) while achieving a high therapeutic effect in excess of this figure, as in the use of Larsa, and sodium hypochlorite. Capocasale comparative tests, result from the use of sodium hypochlorite, having antibacterial, detoxifying, anti-fungal, anti-inflammatory effect in the treatment of diarrhoea of calves was lower than in the treatment claimed by the tool. A similar result was obtained in comparative tests using Larsa.
Research to identify the optimal ratio of components in the medicinal product were conducted in three experiments 570 calves up to 1.5 months of age 9-10 calves in the group. Each experience was different from the previous daily dose of the drug (75, 150, 225 ml), giving to drink with colostrum or milk in three steps, i.e. at 25, 50, 75 ml for the reception, respectively. In the experiments, we studied the efficiency of the medicines when the content of sodium hypochlorite from 250 to 450 mg/l in combination with four sets (sets), consisting of polyvinylpyrrolidone, furatsilina, glucose. Each kit is different from the previous higher content of substances, the content of ascorbic acid in all the sets remained at the level of 4 g/HP Kit # 1: polyvinylpyrrolidone - 8, furatsilin 4, glucose 15 g/l, set No. 2 - 9; 5; 18, kit No. 3 - 10,0; 6,0, kit # 4 - 11; 6,5; 23 g/l, respectively.
Research results are reflected in table 1. Experiments on the application of sodium hypochlorite with concentratie mg/l are not reflected in this table due to false the difference between the results when the concentration of 400 mg/L.
As can be seen from table 1, the duration of treatment of diarrhoea of calves was significantly reduced with increasing content of the activity of sodium hypochlorite in the medical facility. For example, in the first experiment using the first set of other components, the duration of treatment decreased from 126 hours when the content of sodium hypochlorite 250 mg/l to 89 hours, while the content of 400 mg/l (reduction in the duration of treatment 29%). At higher concentrations of polyvinylpyrrolidone furatsilina, glucose (sets 2 and 4), this indicator has increased from 29%to 39%, which is typical for all three experiments. The increase in the concentration of these substances in the claimed medicinal product (from 1 to 4 sets) also influenced the reduction of the duration of treatment, when the concentration of sodium hypochlorite 250 mg/l in the first set, the duration of treatment was 126 hours.
When using the fourth set of 109 hours (reduction of the duration of treatment from the previous 2%). As can be seen from studies of the dynamics of reducing the duration of treatment was increased in all cases, the use of the second and third sets and was unreliable when using the fourth. At the same time, given the increasing concentration of sodium hypochlorite from 250 to 400 mg/l duration of treatment with what was rasalas 13% when its concentration 250 mg/l (126 to 109 hours), 25% when the concentration of sodium hypochlorite 400 mg/l (from 89 to 67 hours). Similar dynamics reduce the duration of treatment was maintained in all three experiments. The optimum content of the components of the medicinal product on the basis of this experience, you should consider sodium hypochlorite with a concentration of active substance from 300 to 350 mg/l when the content of the polyvinylpyrrolidone 9-10 g/l, furatsilina 5-6 mg/l, glucose 18-20 mg/l with a daily dose of 150 ml. the Duration of treatment with this ranged from 87 hours when the concentration of sodium hypochlorite 300 mg/l to 63 hours at concentrations of 350 mg/l, i.e. from 3.6 to 2.6 days. The use of funds for treatment of diarrhea at a dose of 225 ml provided inaccurate reducing duration of treatment (from 84 to 63 hours) relative to the dose in 150 ml.
Comparative efficacy of treatment of severe diarrhea drugs analogues and the claimed therapeutic agent are shown in table 2.
Analyzing the data of table 2 it should be noted that in contrast to the use of the claimed medicinal products in the treatment of severe forms of (toxic) diarrhea is possible to reduce the duration of disease on average by 36%, to reduce the mortality of calves on 53-71%, while the gain in live weight at 30 days after treatment were higher on 15-44%. Safety of the calves increased from 80 to 95%.
|№ p/p||Indicators||The experimental group|
|gentamicin||Hypo-chlorite sodium||Lars||the claimed tool|
|1||The number of sick animals, a goal.||130||135||135||140||145|
|2||The live weight of the experimental calves, kg||32±2||38±5||34±3||32±3||34±2|
|3||The dose of the medicinal product||3 mg/kg of body weight of the calf 2 times a day||500 ml 2 times a day||according to the instruction||50 ml 3 times a day||75 ml 2 times a day|
|4||Mean disease duration, days||4,5||4,2||the 4.7||2,8||2,9|
|7||Average daily weight gain (g) at 30 days after treatment||to 300.7||of 306.7||375,3||435,2||430,4|
Production (manufacturing) of the drug is hanging powdery substances according to the invention is based g/l, for example (polyvinylpyrrolidone 9 g, furatsilin 5 g, 18 g glucose, ascorbic acid 4 g, sodium hypochlorite with a concentration of 300-350 mg/l to liters). A portion of powdery substances made in the calculation for a certain number of finished medicinal product, for example 10-20-50-100 liters and more.
The powdered mixture of four substances specified in the formula, pre-screened, lumps are crushed, all filled to capacity corresponding to the size and quantity of the sample, filled with sodium hypochlorite with a concentration of 300-350 mg/l, thoroughly mixed until complete dissolution of all components (homogeneous suspension).
The resulting tool is Packed in a prepared container (0.5, 1,5, 2,0, 2,5 l glass, plastic bottles, cans), tightly sealed, and labeled. Store protected from light place at a temperature of from +1 to +20°C.
Example 1. At the farm, at the first sign of disease of calves (10 goals, in a separate group) opened the container with Lekarstvo the m by means of the calculation of 150 ml to 1 calf per day, i.e. polutoralitrovom bottle (150 ml × 10 goals) and vapiwala with milk or colostrum three times 50 ml per feeding on each calf.
Example 2. At the first sign of disease of calves (20 goals in a separate group) revealed two capacity 1.5 litres of medicines (150 ml × 20 goals) and vapiwala twice in 75 ml (morning and evening) for one feeding.
Thus, the claimed medicinal product for the treatment of diarrhoea in calves provides high efficiency, expressed in enhancing the security of calves, the reduction of treatment time, with a small dose of the drug, increased average daily gain after treatment. In addition, significantly reducing the consumption of polyvinylpyrrolidone and glucose.
The use of a drug in the treatment of diarrhoea in calves in 20 farms Altai region confirmed its high efficiency.
Drug for the treatment of diarrhoea in calves, including polyvinylpyrrolidone, furatsilin, glucose, ascorbic acid, characterized in that it additionally contains sodium hypochlorite with a concentration of 300-350 mg/l at the following ratio of components, g/l:
|gluco is and||18-20|
at the same daily dose of the medicinal product, giving to drink 2-3 reception is not more than 150 ml
FIELD: medicine; pharmacology.
SUBSTANCE: invention concerns a combination for proliferative disease treatment which contains antidiarrheal agent and epothylon derivative of formula (1) or epothylon derivative, method of diarrhoeia management, associated with epothylon introduction of formula (1), pharmaceutical composition, trade packing and medical product, including antidiarrheal agent and epothylon derivative.
EFFECT: compositions have improved efficiency.
9 cl, 6 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to antagonists of adenosine A2B receptors and their using in treatment of mammals in different pathological states, such as digestive, immunological, neurological disorders and cardiovascular diseases caused both hyper-proliferation of cells and their apoptosis and similar disorders. Also, invention relates to methods for synthesis of these compounds and pharmaceutical composition containing thereof. The aim of the present invention is use of compounds of the general formulae (I) and (II) for preparing pharmaceutical composition possessing antagonistic activity with respect to adenosine A2B receptors wherein radical values are given in the invention description.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
41 cl, 12 sch, 35 ex
SUBSTANCE: means has 0.001-0.05 mg of Ramozetron Hydrochloride as daily dose or equivalent molar quantity of Ramozetron or its other pharmaceutically permissible salt as active ingredient.
EFFECT: enhanced effectiveness of treatment.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to pharmaceutical compositions with anti-diarrheic effect. Pharmaceutical composition comprises the therapeutically effective amount of loperamide hydrochloride as an active component and special additives. Lactose, starch, aerosil, talk and stearate are used as special additives. Pharmaceutical composition is prepared in the form of solid gelatinous capsules. Loperamide capsules satisfy all requirement of the State Pharmacopoeia of XI Edition. Invention provides bioavailability of the pharmaceutical composition of loperamide capsules at the level 98.5%.
EFFECT: improved and valuable pharmaceutical properties of composition.
3 cl, 1 tbl, 3 ex
FIELD: veterinary science.
SUBSTANCE: the suggested preparation for treating diarrhea in farm animals youngsters contains bismuth salt in the form of bismuth-potassium ammonium citrate and, additionally, polyethylenoxide, moreover, preferably, it contains 1.5-2.5%-polyethylenoxide solution and 1.5-2.5%-bismuth-potassium ammonium citrate solution. The method for treating diarrhea deals with introducing the above-mentioned preparation once or twice daily for 1-2 d at the dosage of 1-75 ml/kg body weight. In young foxes it should be introduced at the dosage of 60-75 ml/kg body weight, in calves - at the dosage of 1-3 ml/kg body weight, in lambs - at the dosage of 2-3 ml/kg body weight. Application of the present complex preparation and therapeutic method enables to shorten terms of therapy by 1.5-2 times, decreases expenses for therapy by 3-5 times and provides decreased toxicological impact the preparation upon animal body.
EFFECT: higher efficiency of therapy.
6 cl, 3 ex, 2 tbl
SUBSTANCE: infusion detoxification, antispasmodic, hepatoprotective therapies is combined with diet. In 4-5th day of disease is prescribed infusion of collection №1 containing oak bark, melilot herb, licorice roots, coltsfoot leaves, motherwort leaves, cudweed leaves, Echinacea herb at ratio of components 2:2:2:2:2:1:1:1:1, dosed 1/3 glass 3 times a day, 30 min before meal within 14 days. In phase of remission is prescribed appoint infusion of collection №2 containing inula rhizomes and roots, calendula blossom, nettle leaves, plantain leaves, hips, green ginger herb, haricot leaves, Echinacea herb at ratio of components 2:2:2:2:2:1:1:1 respectively dosed 1\3 glass 3 times a day 30 min before meal within 4 weeks for relapse prevention.
EFFECT: provides accelerated normalisation of clinical laboratory indicators, prevents aggravations.
3 cl, 1 tbl, 1 ex
SUBSTANCE: antibacterial and rehydration therapies are combined with prescribed sorbents, symptomatic therapy. From first day of disease prescribed is infusion herb collection consisting of silverweed rhizome, salvia leaves, milfoil herb, St. John's wort herb, inula rhizomes with roots, tickseed herbs, mint leaves, fennel fruits and buckthorn bark at ratio of components 2:2:2:2:2:2:2:2:1. Infusion is taken up dosed 1\3 glass 3 times a day, 30 min before meal within 10 days. Then within three weeks after basic therapy appoint infusion from silverweed rhizome, salvia leaves, milfoil herb.
EFFECT: provides accelerated normalisation of clinical-laboratory indicators, and prevention of infectious complications without by-effects.
2 cl, 1 tbl, 1 ex
SUBSTANCE: before an injection, put an ice cap to the place of prospective administration. After development of proof cryo hyperemia intravenously inject cooled to 18-20°C a 4% solution of potassium chloride. In case of erroneous introduction of a potassium chloride solution in tissues, remove the needle from a syringe and leave on an injection place; on injection area put an ice cap. The second syringe through the left needle, inject cooled to 18-20°C solution of lidocaine hydrochloride of 1% in the volume peer to volume of the entered solution of 4% of potassium chloride.
EFFECT: increase of efficiency of protection of tissues from acute postinjection damage at introduction of preparations of a potassium at the expense of reduction of requirement of the cooled infiltrate in arterial blood, improvements of diffusion and excision of a preparation of potassium.
FIELD: medicine, veterinary medicine.
SUBSTANCE: invention relates to pharmacology, particularly compositions for complex therapy of intoxications and critical states in animals. The complex therapy composition for intoxications in animals contains: glucose, succinic and ascorbic acids, sodium and calcium chlorides, sodium hydroxide, and distilled water, in following proportion of ingredients: 250 g glucose, 10 g succinic acid, 2 g ascorbic acid, 7 g sodium chloride, 2 g calcium chloride, 10 g sodium hydroxide, and distilled water to 1000 ml, solution pH = 6.3 to 6.4.
EFFECT: provides high anti-hypoxic and anti-oxidant activity of the composition in therapy for intoxications and critical states of various etiologies.
2 tbl, 1 ex
FIELD: medicine, veterinary medicine.
SUBSTANCE: invention relates to veterinary medicine and can be applied in clinical practice, particularly in complex therapy for toxico-infectious diseases in animals. The complex therapy composition for toxico-infectious diseases in animals is featured by the next ingredients: succinic acid, glucose, sodium chloride, calcium chloride, sodium hydroxide, Dorogov's antiseptic-stimulator fraction 2 (ASD f-2), distilled water, in following proportion: 10 ml ASD f-2, 10 g succinic acid, 250 g glucose, 7 g sodium chloride, 2 g calcium chloride, 10 g sodium hydroxide, and distilled water to 1000 ml, solution pH = 7.0.
EFFECT: providing of high therapeutic efficiency of the composition in acute toxico-infectious diseases in animals.
2 tbl, 1 ex
SUBSTANCE: invention relates to medicine, particularly anaesthesiology, and can be applied as anaesthetic aid in extremities surgery. In such cases the multi-component mix is perineurally injected, consisting of 1% lidocaine solution, 0.1 mg phentanile, 50 mg thiamine bromide, 0.2 mg epinephrine, and 0.2 mg clopheline. At the same time 100 mg ketamine diluted in 400 ml 0.9 % NaCl solution is intravenously injected at speed 90 to 120 drops per minute.
EFFECT: anaesthesia efficiency and safety increasing, due to anaesthesiology protection in different levels by mutual anaesthetics potentiation.
2 tbl, 1 ex
FIELD: medicine; oncology.
SUBSTANCE: from the first day of treatment centrifugate the autoblood obtained by vascular access in volume of 2400-2600 ml, 1600 ml of supernatant plasmas select in sterile vials, expose to filtrational detoxicating with use of filter F60S with rate of perfusion of 250-300 ml/minute. Then the obtained albuminous concentrate of autoplasma in volume 700-800 ml place in sterile vials in the equal portions corresponding to number of planned introductions of cytostatics under the scheme. Vials contain in a refrigeration cabinet at t-20°C. At carrying out of polychemotherapy by cytostatics under the scheme, an albuminous concentrate defreeze at t +4°C, each antitumoral preparation plant in 10 ml of a normal saline solution, enter into a vial with an albuminous concentrate, incubate at t +37.0°C within not less than 30 minutes and reinfuse them intravenously driply, spend 1-2 courses of neoadjunt treatment.
EFFECT: increase of efficiency of treatment at the expense of transfer of patients in an operable condition; reduction of the sizes of a tumour and lymphonoduses and depression of toxicity of spent polychemotherapy.
SUBSTANCE: before the patient is placed into anti-shock suite (ASS) "Kashtan", the crystalloids solution infusion in dose 5-7 ml/kg of body weight is performed during 10-15 min. Then the patient is placed into ASS "Kashtan", and pneumocompression is applied over injured body parts up to 40 mm Hg, and over the rest parts 15-20 mm Hg. In first 30 min. of transportation the crystalloids solution is infused in dose 10-15 ml/kg of body weight. In addition, voluven is administered in doses as follows: in shock degree I - 10 to 15 ml/kg of body weight, in shock degree II - 20 to 25 ml/kg of body weight, in shock degree III - 30 to 35 ml/kg of body weight. The method provides sparing transportation of patients, including long-time transportation, owing to fast normalisation of central hemodynamics indices by the developed regimen of compression application in ASS, simultaneously with hypovolemia correction subject to shock degree.
EFFECT: sparing transportation of victim.
6 tbl, 3 ex, 1 dwg
SUBSTANCE: invention can be used at the infiltrates caused by introduction of a hyperosmotic solution of a medical product in a tissue. For this purpose localisation and the size of an infiltrate are defined immediately, a needle is left in the place of injection. The method further includes defining an indicator of osmotic activity and volume of the solution ingected; detaching a needle from a syringe and injecting a water for injection cooled to 0°C into tissues with the second syringe in the volume providing normalisation of osmotic pressure of the solution injected with the subsequent applying of a bubble with ice for not less than 30 minutes. As first, half of the volume is injected in the form of consecutive injections on peripheries of the infiltrate formed, the other half of the volume being injected, through the needle left, into its central part.
EFFECT: method allows for preventing development of postinjection necrosis before an irreversible stage of inflammation thanks to depression of size of osmotic pressure of hyperosmotic agent injected.
SUBSTANCE: premedication by suprastin is performed in the dose of 0.25 mg/kg, in 15 minutes before anesthetic induction intravenous injection of 6-7.5 ml/kg of plasmalyte solution. Anesthesis induction is performed with 0.013 mg/kg of atropine and 1.33 mcg/kg of fentanil, then 2.5-3 mg/kg of propofol followed by 0.6 mg/kg of atracurium is injected. In 2 minutes after achievement of adequate mioplegia laryngoscopy and trachea intubation are performed. Anesthesia is sustained by low-flow anesthesia based on sevoflurane with minimum alveolar concentration of 1.2-0.6 in air and oxygen mix flow of 1.2-1.4 l/min via half-closed circuit in the IPPV mode, with tidal volume (TV)=7-8 ml/kg and minute tidal volume (MTV)=78-85 ml/kg, FiO2=40% under control of SpO2 and EtCO2. During anesthesia mioplegia is sustained by infusion of 0.36 mg/kg/hour of atracurium. If the operation should involve collapsed lung expansion, then sevoflurane feed is stopped at the moment of toracal drainage installation, in 8-10 min before the expansion, and fresh air and oxygen mix feed reaches 1.2-1.4 l/min in half-closed circuit with FiO2=40% with previous breath parametres. In 2 minutes before the collapse lung expansion anesthesia is deepened by injection of 1.25-1.5 mcg/kg of fentanil. If the operation is performed for a patient with complicated spine trauma, additionally 30 dose units of ingitryl is applied.
EFFECT: reduced surgical stress for patient and prevention of stress-induced response to surgical aggression.
1 ex, 3 cl
SUBSTANCE: invention is characterised by that produced bactericidal water-dispersion solution consists of silver nanoparticles, surface-active substance (SAS) and water with size distribution of particles. The second subject is production method of this solution by silver ion restoration in reciprocal micelle system including preparation of SAS micelle solution in nonpolar solvent from: n-hexane, or n-heptane, or n-octane, or n-decane, or cyclohexane, or isooctane with reducing agent added. Aqueous silver salt solution is prepared with ammonia solution. Produced two-phase system is settled with following aliquation and separation of organic layer of base aqueous silver nanoparticles solution of reducing agent from group flavonoids, e.g. quercetin.
EFFECT: enables production of high effective bactericidal agent with high biological activity associated with microorganisms which keeps for a long time.
4 cl, 8 tbl, 1 dwg, 8 ex